Subcutaneous Adipose Tissue in Cases With Polycystic Ovarian Syndrome

This study has been completed.
Sponsor:
Information provided by:
Gulhane School of Medicine
ClinicalTrials.gov Identifier:
NCT01310569
First received: March 7, 2011
Last updated: NA
Last verified: August 2010
History: No changes posted

March 7, 2011
March 7, 2011
January 2009
August 2010   (final data collection date for primary outcome measure)
Relationship of Subcutaneous Adipose Tissue with HOMA-IR and Plasma Adiponectin Levels in Cases with Polycystic Ovarian Syndrome [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]
PCOS patients (the experimental group) had higher mean SFT values in all parts, mid-upper arm circumference values, whole body and trunk fat free mass amounts (FFM) and HOMA-IR values, while a lower adiponectin level.
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Subcutaneous Adipose Tissue in Cases With Polycystic Ovarian Syndrome
Relationship of Subcutaneous Adipose Tissue With HOMA-IR and Plasma Adiponectin Levels in Cases With Polycystic Ovarian Syndrome

This study aimed to search whether whole body and subcutaneous adipose tissues increase in PCOS patients and whether these tissues are related to HOMA-IR and plasma adiponectin levels.

Fifty-two patients with PCOS and fifty-tree healthy controls who were matched for body mass index (BMI) and age (p=0.430, p=0.112, respectively) were enrolled in the study. Biceps, triceps, subscapular and suprailiac skinfold thicknesses (SFT) of all cases were measured via caliper device; mid-upper arm circumference (MUAC) via a tape; and body fat distributions via a bioelectrical impedance device. Insulin resistance was calculated via HOMA-IR while ELISA was used to measure plasma adiponectin.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with PCOS witout any other metabolik diseases

Polycystic Ovary Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
52
August 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All of the women with PCOS had normal thyroid-stimulating hormone and prolactin (PRL) levels.

Exclusion Criteria:

  • Subjects with possible ovarian tumors, congenital adrenal hyperplasia, BMI greater than 35 kg/m2, any chronic renal or liver disease, were excluded from the study.
Female
18 Years to 42 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Turkey
 
NCT01310569
27.04.2010/1491-764-10
No
Aydogan Aydogdu, Gulhane School of Medicine
Gulhane School of Medicine
Not Provided
Study Director: Aydogan Aydogdu, MD Gulhane School of Medicine
Gulhane School of Medicine
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP